ANV-419

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential May 29, 2024 -- Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I/II study evaluating the safety and clinical activity of ANV600 has been accepted by the FDA. The Company will initiate the first two dose escalation cohorts with ANV600 monotherapy and combination with MSD’s (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as part of a multi cohort study to evaluate the safety and efficacy of ANV600 in multiple cancer indications. ANV600 uses a non-blocking anti-PD-1 antibody to target a powerful IL-2Rβ/γ selective IL-2 agonist to tumor-specific T cells, resulting in their proliferation and increase of tumor-killing potential. ANV600 is designed to administer in combination with approved PD-1 checkpoint inhibitors, thus enabling optimal dosing of IL-2 agonism and PD-1 blockade to maximize therapeutic benefit. “Approval to start our first-in-human clinical study of ANV600 represents an important step towards validation of our approach,” said Eduard Gasal, M.D., Chief Medical Officer of Anaveon. “In preclinical studies, ANV600 has demonstrated marked efficacy and a favorable safety profile. We are eager to bring this potential treatment option to patients.” In March 2024, Anaveon entered into a clinical trial collaboration and supply agreement with MSD, to evaluate Anaveon’s wholly-owned drug candidate ANV600 in combination with KEYTRUDA in clinical trials. Under the terms of the agreement, MSD will supply KEYTRUDA. Anaveon retains all worldwide rights to ANV600. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Anaveon is a biotechnology company located in Basel, Switzerland. Using our immunological knowledge and expertise in protein engineering, we develop medicines to deliver meaningful benefits to cancer patients. Our lead compounds, ANV419 and ANV600, are currently in clinical trials in solid tumors. The content above comes from the network. if any infringement, please contact us to modify.

ANV600 is a potent, cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for Cancer Research (AACR) 23rd Annual Meeting being held from Friday, April 14, 2023, to Wednesday, April 19, 2023, in Orlando, Florida. ANV600 is a novel bispecific compound, comprising an anti-IL-2 antibody/IL-2 fusion protein and a proprietary hPD-1 binding moiety for specific delivery of IL-2 to tumor antigen experienced PD-1+ T cells. ANV600 treatment leads to a dose-dependent increase of intratumoral, stem-like and cytotoxic PD-1+T cells in mice harboring B16F10 and MC38 subcutaneous tumors and markedly retards tumor growth. “ANV600 is a powerful, new, targeted therapeutic with the potential to extend the benefits of IL-2 therapies to less immunogenic tumors,” said Christoph Huber, Chief Scientific Officer of Anaveon. “We plan to initiate clinical studies in early 2024 to determine the therapeutic benefit in patients.” The abstract will be published on Friday, March 31 on an online-only Proceedings supplement to the AACR journal Cancer Research. The accompanying poster will be on display on Anaveon’s website on April 14, 12:00 pm EDT. Details of the poster presentation: Tuesday, April 18, 9:00 am – 12:30 pm EDT, Poster #4127 Title: ANV600 is a potent, cis-signaling, non-alpha IL-2 agonist which efficiently expands intratumoral stem-like CD8 T cells Authors: P. Murer, U. Salazar, N. Egli, L. Petersen, P. Neubert, K. Richter, Ch. Stocker, A. Rau, A. Katopodis and Ch. Huber Anaveon is developing selective cytokine receptor agonists with the potential to therapeutically enhance a patient’s immune system to respond to tumors. ANV419, currently in Ph II studies in multiple cancer indications, is designed to preferentially signal through the IL-2 beta/gamma receptor resulting in strong proliferation of effector cells in patients. The follow-on compound, ANV600, targets the selective IL-2 receptor moiety to intratumoral effector cells and may have therapeutic benefit in less immunogenic tumors. These novel types of therapeutics, if approved, could potentially have a wide utility in oncology, including in combination with checkpoint inhibitors, cell therapies, vaccines, and radiotherapy. Enquiries JW Communications Julia Wilson Email: Julia.wilson@anaveon.com Tel: +44 (0)7818 430877 About Anaveon: Anaveon is a clinical stage, biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology. For further information please visit the Company’s website at: .